Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy
Clinical trial NCT02448290 · COMPLETED
Trial details
- NCT number
- NCT02448290
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-12
- Primary completion
- 2018-05-17
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.